Press Releases Poolbeg Pharma PLC

Stocks

POLB

GB00BKPG7Z60

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 09:05:26 17/07/2026 pm IST			5-day change	1st Jan Change
6.150 ^GBX	0.00%		-12.14%	+53.75%

15/07	Poolbeg Pharma raises GBP3.5 million in share placing	AN
14/07	WINNERS & LOSERS: Ironveld's plant in production; Headlam revenue down	AN

Press Releases

23/25/23	POLB 001: tackling cytokine storms before they start	AQ
19/25/19	Form 8.5 (EPT/RI) - Poolbeg Pharma Plc	AQ
05/25/05	Form 8.5 (EPT/RI) - Poolbeg Pharma Plc	AQ
21/25/21	Form 8.5 (EPT/RI) - Poolbeg Pharma Plc	AQ
03/25/03	Form 8.5 (EPT/RI) - Poolbeg Pharma Plc	AQ
22/24/22	University College Dublin : UCD leading on research collaborative agreements with industry, according to latest Knowledge Transfer Ireland Survey	AQ
29/24/29	Poolbeg Pharma plc - Voluntary Delisting from OTCQB Market	AQ
10/24/10	Poolbeg Pharma plc - Annual Report and AGM Notice	AQ
08/24/08	Poolbeg Pharma's POLB 001 immuno-modulator II receives fully-granted patent from US Patent Office	AQ
01/24/01	Poolbeg Pharma and Silk Road Therapeutics announce strategic collaboration on novel orphan drug	AQ
01/24/01	Poolbeg Pharma plc - Appointment of Joint Broker	AQ
23/24/23	Poolbeg Pharma plc - Director Share Purchase	AQ
20/24/20	Poolbeg Pharma plc - Director Share Purchase	AQ
20/24/20	Poolbeg Pharma chair discusses shift to executive role; hVIVO share sale	AQ
12/24/12	Poolbeg Pharma says research confirms $10B plus opportunity for POLB 001 in cancer immunotherapies	AQ
08/24/08	Poolbeg Pharma's new VP of Clinical Operations Laura Maher aims to help progress development assets	AQ
18/24/18	Poolbeg Pharma plc - Further Data Confirms POLB 001's Potential in Cancer Immunotherapy-Induced Cytokine Release Syndrome	AQ
12/23/12	Poolbeg Pharma plc - POLB 001 Data Presented at ASH	AQ
22/23/22	Poolbeg Pharma plc - Immunomodulator II patent granted in Japan	AQ
17/23/17	Poolbeg Pharma plc - POLB 001 LPS Challenge Trial Data to be presented at IUIS	AQ
02/23/02	Poolbeg Pharma "continuing its campaign to find a partner" for POLB001	AQ
18/23/18	Poolbeg Pharma unveils new collaboration agreement	AQ
13/23/13	Poolbeg Pharma "moving forward rapidly" with POLB001	AQ
29/23/29	Poolbeg Pharma and CytoReason identify "very exciting influenza targets"	AQ
22/23/22	Poolbeg Pharma sees "significant commercial opportunity" in oral vaccines	AQ